![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
554kB |
![[thumbnail of Supplemental Material]](https://edoc.mdc-berlin.de/style/images/fileicons/application_msword.png) |
MS Word (Supplemental Material)
254kB |
| Item Type: | Letter |
|---|---|
| Title: | Genotype and intensive pretreatment influence outcome of acute myeloid leukemia patients treated with venetoclax in combination with hypomethylating agents or low-dose cytarabine: "real world" data from germany |
| Creators Name: | Braitsch, K., Schmalbrock, L.K., Jung, P., Bumeder, I., Kiewe, P., Hecker, J.S., Verbeek, M., Westermann, J., Bullinger, L., Keller, U., Bassermann, F., Krönke, J., Götze, K.S. and Rieger, K. |
| Source: | HemaSphere |
| ISSN: | 2572-9241 |
| Publisher: | Wolters Kluwer |
| Volume: | 6 |
| Number: | 9 |
| Page Range: | e759 |
| Date: | September 2022 |
| Official Publication: | https://doi.org/10.1097/HS9.0000000000000759 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
